#USA #San Diego #oncology #Okomera #SLAS2025

Okomera's Cutting-Edge Organoid Screening Technology at SLAS 2025

Okomera, an emerging player in the biotech field, is making waves with its groundbreaking technology designed for oncology drug discovery. Attendees at the upcoming SLAS 2025 event, scheduled from January 25 to 29 in San Diego, will witness firsthand the capabilities of Okomera's Automated Desktop Organoid Screening Instrument. This innovative high-throughput platform integrates proprietary microfluidic chips with advanced AI-powered software to enhance preclinical drug testing and fine-tune precision oncology research.

A significant aspect of Okomera's presentation will be a detailed exploration of their poster titled "End-to-End Automated Organoid Screening Platform Application in Breast Cancer Drug Screening." This poster will showcase collaborative results from joint efforts with renowned medical professionals from Gustave Roussy. Notable collaborators include Dr. Pierre Savagner of INSERM, Dr. Natacha Joyon, a breast cancer pathologist, Dr. Barbara Pistilli, a medical oncologist involved with breast pathology, and Dr. Benjamin Verret, who specializes in sarcomas and breast cancer.

The collaborative research underscores Okomera's ability to produce reproducible 3D organoids from patient-derived xenografts (PDX). The platform excels in screening a variety of drugs under different conditions, providing researchers with a scalable solution for high-throughput drug discovery while ensuring the preservation of scarce patient samples. Future endeavors aim to extend the platform's utilization to include biopsy-derived samples, paving the way for advancements in personalized oncology research.

Sidarth Radjou, CEO of Okomera, highlights the significance of these collaborations, stating, "Working with leading clinicians from Gustave Roussy provides a strong foundation for advancing our platform toward real-world applications." He emphasizes the mission of Okomera to equip pharmaceutical companies and clinical researchers with high-throughput, scalable tools crucial for effective oncology drug discovery.

What sets Okomera's platform apart is its seamless integration of automated organoid generation, multiplexed drug screening, and AI analysis within a single workflow. This system's unique capability to co-culture diverse cell types while testing various conditions makes it a highly effective solution for preclinical drug research, ultimately helping to streamline processes and reduce costs.

Founded in 2020 as a spin-off from École Polytechnique, Okomera boasts a patented technology that has evolved through ten years of dedicated research at Pasteur Institute and École Polytechnique. The company's ambitious goal is to catalyze pharmaceutical innovation by refining drug discovery methodologies through its cutting-edge microfluidics and AI applications.

Attendees at SLAS 2025 are encouraged to stop by booth #3350 to explore Okomera's innovative technology and discover more about its collaborative research initiatives.

For further information, you can visit Okomera's official website at www.okomera.com.